Nomura Establishes Japanese Generics And Biotech Investment Funds
This article was originally published in PharmAsia News
Executive Summary
Japanese investment bank Nomura announced June 18 that it would establish investment funds containing a basket of generic drug makers and biotech companies June 24. Nomura Asset Management hopes to capitalize on current and future growth in the sectors. Japanese generic makers' share prices jumped on the news. Towa Pharmaceutical led the pack with ¥220 up for the day, marking a new high for the year. Saiwai Pharmaceutical's share price also increased by ¥170 to ¥5,270, also a new high for Japan's largest generic maker. Nichi-Iko shares rose for four days in a row. Another maker Fuji Pharmaceutical, however, saw shares drop by ¥18 due to heavy dependence on a single distributor. Since a diagnostic procedure combined payment system is expanding among hospitals in Japan, the generic drug market is expected to grow further. (Click here for more - Japanese language
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.